- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates | 40 | GlobeNewswire (Europe) | "Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts... ► Artikel lesen | |
| Di | Channel Therapeutics finalizes corporate restructuring | - | Investing.com | ||
| Mo | Channel Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Chromocell Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10. | Chromocell announces amendment to stock repurchase plan | 1 | Seeking Alpha | ||
| CHANNEL THERAPEUTICS CORPORATION Aktie jetzt für 0€ handeln | |||||
| 24.10. | Chromocell boosts stock buyback plan to $750,000 | 1 | Investing.com | ||
| 24.10. | Chromocell Therapeutics Announces Amendment to Stock Repurchase Plan | 1 | GlobeNewswire (USA) | ||
| 24.10. | Chromocell Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | Chromocell therapeutics director buys $9.8k in stock | 1 | Investing.com | ||
| 16.09. | Chromocell therapeutics CEO buys $5,044 in company stock | 1 | Investing.com | ||
| 12.09. | Chromocell Therapeutics CEO buys shares worth over $10,000 | 1 | Investing.com | ||
| 13.08. | Chromocell Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Chromocell Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 07.08. | Chromocell announces stock repurchase plan | 1 | Seeking Alpha | ||
| 07.08. | Chromocell Therapeutics Announces Stock Repurchase Plan | 1 | GlobeNewswire (USA) | ||
| 29.07. | Chromocell Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.07. | Chromocell Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 15.07. | Chromocell Therapeutics to Participate in the Virtual Investor Lunch Break Series | 1 | GlobeNewswire (USA) | ||
| 17.04. | Pre-market Movers: INVO Bioscience, iLearningEngines, Vanda Pharmaceuticals, CXApp, Chromocell Therapeutics | 540 | AFX News | LOWELL (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.45 A.M. ET).In the Green INVO Bioscience, Inc. (INVO) is up over 73% at $1.35.
Vanda... ► Artikel lesen | |
| 09.04. | Chromocell Therapeutics Issues Letter to Stockholders from Chief Executive Officer | 294 | GlobeNewswire (Europe) | FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment... ► Artikel lesen |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,220 | +3,55 % | DAX fehlen die Impulse. Qiagen deutet Gegenbewegung an | ||
| EVOTEC | 10,070 | +1,67 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
| BEAM THERAPEUTICS | 23,580 | -3,72 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| IMMUNOVANT | 26,540 | 0,00 % | Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? | ||
| BIONTECH | 103,40 | 0,00 % | Die meistgehandelten Produkte: BioNTech verstärkt sich mit Übernahme! | ||
| KEROS THERAPEUTICS | 53,84 | -0,55 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| JANUX THERAPEUTICS | 46,500 | -5,02 % | Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,755 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| GALAPAGOS NV | 24,000 | -0,08 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| AVIDITY BIOSCIENCES | 42,530 | -2,57 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,78 | +0,03 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| BB BIOTECH | 38,650 | 0,00 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| NUVALENT | 92,65 | 0,00 % | Nuvalent-CEO Porter verkauft Aktien im Wert von 2,37 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 36,300 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| ARCTURUS THERAPEUTICS | 17,070 | +5,57 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen |
CHANNEL THERAPEUTICS CORPORATION gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHANNEL THERAPEUTICS CORPORATION finden Sie auf Wallstreet Online.
